Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF), Centene (CNC) and LifeMD (LFMD)

Tipranks - Thu Mar 12, 4:34AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Roche Holding AG (RHHVFResearch Report), Centene (CNCResearch Report) and LifeMD (LFMDResearch Report).

Claim 70% Off TipRanks Premium

Roche Holding AG (RHHVF)

In a report released today, Luisa Hector from Berenberg Bank maintained a Hold rating on Roche Holding AG, with a price target of CHF340.00. The company’s shares closed last Tuesday at $438.21.

According to TipRanks.com, Hector is a 4-star analyst with an average return of 5.3% and a 58.6% success rate. Hector covers the Healthcare sector, focusing on stocks such as Merck & Company, Sanofi, and AbbVie. ;'>

Roche Holding AG has an analyst consensus of Moderate Buy, with a price target consensus of $450.96, implying a 5.6% upside from current levels. In a report issued on March 2, J.P. Morgan also maintained a Hold rating on the stock with a CHF350.00 price target.

See today’s best-performing stocks on TipRanks >>

Centene (CNC)

Barclays analyst Andrew Mok CFA maintained a Buy rating on Centene today and set a price target of $54.00. The company’s shares closed last Tuesday at $36.40.

According to TipRanks.com, CFA is a 1-star analyst with an average return of -1.8% and a 48.0% success rate. CFA covers the Healthcare sector, focusing on stocks such as Aveanna Healthcare Holdings, Brookdale Senior Living, and Alignment Healthcare. ;'>

Currently, the analyst consensus on Centene is a Hold with an average price target of $44.67, which is a 5.3% upside from current levels. In a report issued on February 25, Truist Financial also reiterated a Buy rating on the stock with a $49.00 price target.

LifeMD (LFMD)

KeyBanc analyst Scott Schoenhaus maintained a Buy rating on LifeMD today. The company’s shares closed last Tuesday at $3.91.

According to TipRanks.com, Schoenhaus has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -14.2% and a 28.8% success rate. Schoenhaus covers the Healthcare sector, focusing on stocks such as Hinge Health, Inc. Class A, Elanco Animal Health, and Veeva Systems. ;'>

Currently, the analyst consensus on LifeMD is a Strong Buy with an average price target of $8.50, a 142.9% upside from current levels. In a report released yesterday, TipRanks – Google also upgraded the stock to Buy with a $3.50 price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.